Mit biomarkers and methods using the same
AssigneeGenentech, Inc.
InventorsSteffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
Life of this patent
Estimating the term…
Abstract
Provided are therapies related to the treatment of pathological conditions, such as cancer.
Claims39
A method for determining MiT biomarker expression, comprising the step of determining whether a sample from an individual expresses MiT biomarker.
3-6. (canceled)
11-15. (canceled)
19-21. (canceled)
24-27. (canceled)
32-35. (canceled)
39-41. (canceled)
43-47. (canceled)
50-52. (canceled)
A method of treating cancer in an individual comprising administering to the individual an effective amount of a MiT antagonist, wherein treatment is based upon the individual having cancer comprising MiT overexpression.
55-57. (canceled)
A method of identifying an individual with cancer who is more or less likely to exhibit benefit from treatment with an anti-cancer therapy comprising a MiT antagonist or predicting whether an individual with cancer is more or less likely to respond effectively to treatment with an anti-cancer therapy comprising a MiT antagonist or predicting the response or lack of response of an individual with cancer to an anti-cancer therapy comprising a MiT antagonist, the method comprising:
- determining presence or absence of a MiT translocation in a sample obtained from the individual, wherein presence of the MiT translocation in the sample indicates that the individual is more likely to exhibit benefit from treatment with the anti-cancer therapy comprising the MiT antagonist or absence of the MiT translocation indicates that the individual is less likely to exhibit benefit from treatment with the anti-cancer therapy comprising the MiT antagonist, or presence of the MiT translocation indicates that the individual is more likely to respond effectively to treatment with the MiT antagonist and absence of the MiT translocation indicates that the individual is less likely to respond effectively to treatment with the MiT antagonist, or presence of the MiT translocation is predictive of response of the individual to the anti-cancer therapy comprising the MiT antagonist and absence of the MiT translocation is predictive of lack of response of the individual to the anti-cancer therapy comprising the MiT antagonist.
59-60. (canceled)
A method of inhibiting proliferation of a nccRCC cancer cell or treating nccRCC in an individual comprising contacting the cancer cell with or administering to the individual an effective amount of a MiT-translocation antagonist.
(canceled)
65-112. (canceled)
Dependencies are inferred from the claim text.